Showing results (1-10 of 112) with videos related to
Sort By:
Pageof 12
Handbook of Experimental Pharmacology|May 9, 2012
Low-molecular-weight heparins: differential characterization/physical characterizationMarco Guerrini, Antonella BisioSeminars in Thrombosis and Hemostasis|September 24, 2002
Active conformations of glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with antithrombin and fibroblast growth factors in solutionMilos Hricovíni, Marco Guerrini, Antonella Bisio, et al.Carbohydrate Polymers|September 25, 2021
Saturated tetrasaccharide profile of enoxaparin. An additional piece to the heparin biosynthesis puzzleCristina Gardini, Antonella Bisio, Giulia Mazzini, et al.Molecules (Basel, Switzerland)|July 5, 2017
Structural Characterization of the Low-Molecular-Weight Heparin Dalteparin by Combining Different Analytical StrategiesAntonella Bisio, Elena Urso, Marco Guerrini, et al.Thrombosis and Haemostasis|November 6, 2009
The tainted heparin story: an updateMarco Guerrini, Zachary Shriver, Antonella Bisio, et al.Journal of Pharmaceutical and Biomedical Analysis|April 25, 2018
Fine structural characterization of sulodexideNoemi Veraldi, Marco Guerrini, Elena Urso, et al.Carbohydrate Research|April 9, 2014
A heparin-like glycosaminoglycan from shrimp containing high levels of 3-O-sulfated D-glucosamine groups in an unusual trisaccharide sequenceSuely F Chavante, Adriana S Brito, Marcelo Lima, et al.Thrombosis and Haemostasis|November 6, 2009
Structural features of low-molecular-weight heparins affecting their affinity to antithrombinAntonella Bisio, Davide Vecchietti, Laura Citterio, et al.Biochemical and Biophysical Research Communications|March 14, 2002
Minimal heparin/heparan sulfate sequences for binding to fibroblast growth factor-1Marco Guerrini, Teresa Agulles, Antonella Bisio, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 12, 2023
Blended Heparin: A new Perspective to Guarantee the Supply of a Life-Saving Drug?Marco GuerriniPageof 12